Organic Active Ingredients TRIZ Cases

Formula I compounds disrupt oncogenic protein interactions to inhibit neoplastic cell growth, addressing inadequate antisense stability.

Fast melt chewable tablets bypass hepatic first pass metabolism via oral mucosal absorption to increase bioavailability and reduce side effects.

Water-soluble solvents stabilize neohesperidin dihydrochalcone in cosmetic formulations, preventing oxidation and phase separation.

Conjugating active molecules with acrylamide polymers masks local toxicity at the injection site while maintaining high solubility and stability.

TAT-fused alpha2d-1 mimetics block receptor binding to resolve unclear molecular mechanisms in neuropathic pain treatment.

Inhibiting miRNA-128 promotes cardiomyocyte mitotic proliferation, replacing fibrotic scar tissue with functional cells to restore heart function.

Merges non-pathogenic bacteria with buffered vitamin C and vitamin D to reduce infection duration while minimizing gastrointestinal side effects.

Dietary supplement formulation with herbal extracts and folic acid derivatives inhibits xanthine oxidase activity.

Specific TDO and IDO inhibitor compounds resolve the contradiction between therapeutic effectiveness and enzyme selectivity through localized molecular design.

Segmentation and intermediary steps purify fluorescein, eliminating pyridine toxicity while reducing sodium chloride impurities.

Pairing cytotoxic ribonucleases with MAPK-pathway inhibitors overcomes treatment complexity while effectively inhibiting ERK-driven cancer cell growth.

Segmented protein panels assess COPD severity by measuring specific biomarker concentrations to resolve prediction reliability versus assessment complexity.

Calculating a TP53 mutation score using weighted exons selects p53-defective tumors, reducing resistance to WEE1 inhibitors.

Measuring RGS protein activity predicts treatment response to KRASG12C inhibitors despite weak intrinsic GTPase function.

Halogenated alkylated disaccharides act as permeation enhancers for therapeutic agents across biological membranes.

Floating gastroretentive tablet maintains buoyancy in gastric acid for 12 hours, resolving suboptimal bioavailability from frequent dosing.

CBP/β-catenin antagonists shift somatic stem cells to asymmetric renewal while forcing cancer stem cells into symmetric differentiation.

High pH basic PEG 400 formulations prevent hydrolysis and impurity formation while reducing urothelial toxicity.

Low gamma EEG sample entropy identifies patients likely to respond to agomelatine, replacing trial-and-error selection with objective biological markers.

A particle size independent production method dissolves ticagrelor in solvent mixtures followed by wet granulation with excipients.

Replacing gelatine with alternative matrix agents removes heat processing needs while maintaining structural strength for fast oral dissolution.

Substituted pyrazole compounds selectively inhibit LPA1 receptors, addressing limited efficacy and specificity in current fibrosis treatments.

Formula I quinazoline antagonists block TLR9 pathways, reducing interferon-alpha production while maintaining immune function and safety.

Low-temperature solid dispersion prevents protein denaturation during emulsification, achieving zero-order release profiles.

Water extraction of Nepeta cataria L. flower spikes yields active compounds that increase melatonin and serotonin levels.

A spray-drying process converts purified 3-fucosyllactose solutions into stable, low-hygroscopic powder forms.

A non-aqueous injectable formulation disperses poorly water-soluble active pharmaceutical ingredients in a hydrophobic lipid vehicle with an amphiphilic agent.

Strawberry plant extract binds to the inhibitory region of NF-kB protein through controlled dark incubation and ethanol extraction.

Benzene derivatives with specific alkyl and amide groups inhibit T cell proliferation, reducing side effects in organ transplant rejection treatment.

Novel crystalline forms of Lumateperone besylate enhance chemical stability and solubility through controlled salt formation processes.

RPN2 inhibitors suppress cancer stem cell colonization and invasion, resolving the difficulty of targeting undetectable stem cells.

Small molecule mediators bind cereblon to alter its surface shape and recruit GSPT1 for targeted proteasomal breakdown.

Selective bicyclic hydroxamic acid inhibitors reduce off-target toxicity by targeting HDAC6, expanding the therapeutic window for disease treatment.

Identifies metastatic risk via IRF7 pathway gene signatures, enabling targeted Type I IFN therapy to prevent disease progression.

Specific imidazole-2-thione derivatives reduce pulmonary artery pressure in pulmonary arterial hypertension treatment.

Novel substituted naphthyridine compounds inhibit hepatitis B virus RNAse H activity to disrupt viral replication.

Optimized lipid excipients bypass first-pass metabolism barriers, enabling rapid therapeutic absorption while maintaining product stability.

A semi-solid support shifts between sol and gel states to enable three-dimensional cell culture.

Agar-agar dry foam delivers reliable arterial occlusion while eliminating ecological concerns from synthetic materials.

A pharmaceutical composition combining zinc gluconate and cyclo-hispro to enhance metabolic regulation.

Selective bicyclic pyrazole inhibitors reduce RORgammaT activity to treat autoimmune diseases without broad immune suppression.

A biphasic ceramic bone substitute enhances anchorage strength in fragile cancellous bone through controlled pharmaceutical release.

Compounds targeting cytochrome bc1 and ATP synthase shorten treatment duration while maintaining efficacy against multi-drug-resistant strains.

Metoprolol oral liquids achieve 18-month shelf-life by adjusting pH to 2.5-5.5 and adding chelating agents to prevent degradation.

Purified limonin glucoside administration lowers circulating liver enzyme concentrations in chronic disease treatment.